Key points are not available for this paper at this time.
New agents, alone or in combination with ruxolitinib, are currently under clinical trial investigation (ClinicalTrials.gov) and preliminary results were presented at the 2022 ASH annual meeting and highlighted in the current review.
Ayalew Tefferi (Sat,) studied this question.